Substance Use Disorders and Neuro-AIDS in the HAART Era

Jeffrey A. Rumbaugh; Avindra Nath

doi:10.1128/9781555815691.ch29

Chapter 29 : Substance Use Disorders and Neuro-AIDS in the HAART Era

Authors: Jeffrey A. Rumbaugh¹, Avindra Nath²

VIEW AFFILIATIONS HIDE AFFILIATIONS

Affiliations: 1: Department of Neurology, Johns Hopkins University, Baltimore, MD 21287; 2: Department of Neurology, Johns Hopkins University, Baltimore, MD 21287

Content Type: Monograph

Publication Year: 2009

Category: Viruses and Viral Pathogenesis

Book DOI: 10.1128/9781555815691

Chapter DOI: 10.1128/9781555815691.ch29

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:

Substance Use Disorders and Neuro-AIDS in the HAART Era, Page 1 of 2

< Previous page | Next page > /docserver/preview/fulltext/10.1128/9781555815691/9781555813697_Chap29-1.gif /docserver/preview/fulltext/10.1128/9781555815691/9781555813697_Chap29-2.gif

Abstract:

This chapter reviews the studies which provide evidence for a synergistic effect of drugs of abuse and human immunodeficiency virus (HIV) infection on brain function. Understanding the interactive mechanisms of this neurodegeneration is critical to our ability to optimize therapy for drug-abusing HIV-infected populations. The chapter discusses the proposed underlying mechanisms of this combined neurotoxicity, the current state of knowledge about the role of highly active antiretroviral therapy (HAART) in this interaction, and implications for future research and therapeutic development. It discusses the evidence that each of the drugs of abuse interacts with HIV infection through influences on the dopaminergic system and by other mechanisms as well. A recent study showed that morphine inhibits CD8-positive T-cell-mediated noncytotoxic anti-HIV activity in latently infected human immune cells, largely by interfering with a gamma interferon signaling pathway. Naltrexone blocked this morphine-induced inhibition. This study suggests that morphine impairs the anti-HIV function of the immune system. In injection drug users, HAART utilization decreases mortality compared to nonutilization, though all injection drug users, with or without HAART utilization, have better survival in the HAART era than in the pre-HAART era. By stopping the interactive mechanisms discussed in this chapter, it would seem reasonable that drug abstinence would halt or potentially reverse the synergistic progression of HIV-associated dementia in drug-abusing individuals. Further work is needed to optimize and develop new strategies for the benefit of the drug-abusing population.

Citation: Rumbaugh J, Nath A. 2009. Substance Use Disorders and Neuro-AIDS in the HAART Era, p 411-423. In Goodkin K, Shapshak P, Verma A (ed), The Spectrum of Neuro-AIDS Disorders. ASM Press, Washington, DC. doi: 10.1128/9781555815691.ch29

Key Concept Ranking

Tumor Necrosis Factor alpha: 0.47673085
Highly Active Antiretroviral Therapy: 0.42768642

0.47673085

Highlighted Text: Show | Hide

Full text loading...

Figures

Substance Use Disorders and Neuro-AIDS in the HAART Era

[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555815691.ch29-1,webId=/content/author/10.1128/9781555815691.ch29-1,properties={foaf_givenname=Jeffrey A., foaf_name=Jeffrey A. Rumbaugh, foaf_surname=Rumbaugh, pub_isAffiliatedWith=[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/affiliation/10.1128/9781555815691.ch29-aff1]]}], com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555815691.ch29-2,webId=/content/author/10.1128/9781555815691.ch29-2,properties={foaf_givenname=Avindra, foaf_name=Avindra Nath, foaf_surname=Nath, pub_isAffiliatedWith=[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/affiliation/10.1128/9781555815691.ch29-aff2]]}]]

/content/10.1128/9781555815691.ch29.ch29fig01

FIGURE 1

MRI scan of a patient with HIV infection who abused heroin and cocaine. This 51-year-old HIV-infected woman used cocaine several days per week and heroin on a regular basis. She was admitted to Johns Hopkins Hospital with the subacute onset of ataxia, postural instability, and severe dementia. Her CD4 cell count was 5 cells/mm3, and her plasma viral load was 436,000 copies/ml. MRI scan shows bilateral hyperintensities in the basal ganglia, without edema.

10.1128/9781555815691/ch29fig1_thmb.gif

10.1128/9781555815691/ch29fig1.gif

FIGURE 1

/content/10.1128/9781555815691.ch29.ch29fig02

FIGURE 2

Synergistic neurotoxicity with HIV proteins and drugs of abuse. Human fetal neurons were incubated with HIV proteins gp120 (g) (30 pM) and Tat (T) (40 nM) at subneurotoxic dosages with or without methamphetamine (meth) (500 µM) or cocaine (16 µM). Changes in mitochondrial membrane potential were measured using JC-1 fluorescent dye. Synergistic neurotoxicity was noted as shown (modified from Turchan et al., 2001 ). Data are presented as mean + standard error of the mean and calculated as percentage of control. Untreated cells were used as control.

10.1128/9781555815691/ch29fig2_thmb.gif

10.1128/9781555815691/ch29fig2.gif

FIGURE 2

References

/content/book/10.1128/9781555815691.ch29

1. Ahern, K.,, H. Lustig, and, D. Greenberg. 1994. Enhancement of NMDA toxicity and calcium responses by chronic exposure of cultured cortical neurons to ethanol. Neurosci. Lett. 165: 211– 214.

2. Aksenov, M.,, U. Hasselrot,, A. Bansal,, G. Wu,, A, Nath,, C. Anderson,, C. Mactutus, and, R. Booze. 2001. Oxidative damage induced by the injection of HIV-1 Tat protein in the rat striatum. Neurosci. Lett. 305: 5– 8.

3. Ammon-Treiber, S.,, and V. Hollt. 2005. Morphine-induced changes of gene expression in the brain. Addict. Biol. 10: 81– 89.

4. Anderson, C.,, G. Tomlinson,, B. Pauly,, F. Brannan,, A. Chiswick,, R. Brack-Werner,, P. Simmonds, and, J. Bell. 2003. Relationship of Nef-positive and GFAP-reactive astrocytes to drug use in early and late HIV infection. Neuropathol. Appl. Neurobiol. 29: 378– 388.

5. Andras, I.,, H. Pu,, M. Deli,, A. Nath,, B. Hennig, and, M. Toborek. 2003. HIV-1 Tat protein alters tight junction protein expression and distribution in cultured brain endothelial cells. J. Neurosci. Res. 74: 255– 265.

6. Anthony, I.,, D. Crawford, and, J. Bell. 2004. Effects of human immunodeficiency virus encephalitis and drug abuse on the B lymphocyte population of the brain. J. Neurovirol. 10: 181– 188.

7. Antoniou, T.,, and A. Tseng. 2002. Interactions between recreational drugs and antiretroviral agents. Ann. Pharmacother. 36: 1598– 1613.

8. Arango, J.,, P. Simmonds,, R. Brettle, and, J. Bell. 2004. Does drug abuse influence the microglial response in AIDS and HIV encephalitis? AIDS 18 (Suppl. 1): S69– S74.

9. Asthana, S.,, S. Craft,, L. Baker,, M. Raskind,, R. Birnbaum,, C. Lofgreen,, R. Veith, and, S. Plymate. 1999. Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer’s disease: results of a placebo-controlled, double-blind, pilot study. Psychoneuroendocrinology 24: 657– 677.

10. Baldwin, J.,, C. Maxwell,, A. Fenaughty,, R. Trotter, and, S. Stevens. 2000. Alcohol as a risk factor for HIV transmission among American Indian and Alaska native drug users. Am. Indian Alsk. Native Ment. Health Res. 9: 1– 16.

11. Bartzokis, G.,, M. Beckson,, T. Newton,, M. Mandelkern,, J. Mintz,, J. Foster,, W. Ling, and, T. Bridge. 1999a. Selegiline effects on cocaine-induced changes in medial temporal lobe metabolism and subjective ratings of euphoria. Neuropsychopharmacology 20: 582– 590.

12. Bartzokis, G.,, M. Beckson,, D. Wirshing,, P. Lu,, J. Foster, and, J. Mintz. 1999b. Choreoathetoid movements in cocaine dependence. Biol. Psychiatry 45: 1630– 1635.

13. Basso, M.,, and R. Bornstein. 2000. Neurobehavioural consequences of substance abuse and HIV infection. J. Psychopharmacol. 14: 228– 237.

14. Bell, J.,, R. Brettle,, A. Chiswick, and, P. Simmonds. 1998. HIV encephalitis, proviral load and dementia in drug users and homosexuals with AIDS. Effect of neocortical involvement. Brain 121: 2043– 2052.

15. Bennett, B.,, D. Rusyniak, and, C. Hollingsworth. 1995. HIV-1 gp120-induced neurotoxicity to midbrain dopamine cultures. Brain Res. 705: 168– 176.

16. Berger, A.,, H. Schaumburg,, M. Gourevitch,, K. Freeman,, S. Herskovitz, and, J. Arezzo. 1999. Prevalence of peripheral neuropathy in injection drug users. Neurology 53: 592– 597.

17. Berger, J.,, and G. Arendt. 2000. HIV dementia: the role of the basal ganglia and dopaminergic systems. J. Psychopharmacol. 14: 214– 221.

18. Berger, J.,, and M. Avison. 2004. The blood brain barrier in HIV infection. Front. Biosci. 9: 2680– 2685.

19. Berger, J.,, M. Kumar,, A. Kumar,, J. Fernandez, and, B. Levin. 1994. Cerebrospinal fluid dopamine in HIV-1 infection. AIDS 8: 67– 71.

20. Bidlack, J. 2000. Detection and function of opioid receptors on cells from the immune system. Clin. Diagn. Lab. Immunol. 7: 719– 723.

21. Boess, F.,, F. Ndikum-Moffor,, U. Boelsterli, and, S. Roberts. 2000. Effects of cocaine and its oxidative metabolites on mitochondrial respiration and generation of reactive oxygen species. Biochem. Pharmacol. 60: 615– 623.

22. Bohn, L.,, M. Belcheva, and, C. Coscia. 2000. Mu-opioid agonist inhibition of kappa-opioid receptor-stimulated extracellular signal-regulated kinase phosphorylation is dynamin-dependent in C6 glioma cells. J. Neurochem. 74: 574– 581.

23. Bornstein, R.,, R. Fama,, P. Rosenberger,, C. Whitacre,, M. Para,, H. Nasrallah, and, R. Fass. 1993. Drug and alcohol use and neuropsychological performance in asymptomatic HIV infection. J. Neuropsychiatry Clin. Neurosci. 5: 254– 259.

24. Bouwman, F.,, R. Skolasky,, D. Hes,, O. Selnes,, J. Glass,, T. Nance-Sproson,, W. Royal,, G. Dal Pan, and, J. McArthur. 1998. Variable progression of HIV-associated dementia. Neurology 50: 1814– 1820.

25. Brannvall, K.,, N. Bogdanovic,, L. Korhonen, and, D. Lindholm. 2005. 19-Nortestosterone influences neural stem cell proliferation and neurogenesis in the rat brain. Eur. J. Neurosci. 21: 871– 878.

26. Brooks, P. 1997. DNA damage, DNA repair, and alcohol toxicity—a review. Alcohol Clin. Exp. Res. 21: 1073– 1082.

27. Cass, W.,, M. Harned,, L. Peters,, A. Nath, and, W. Maragos. 2003. HIV-1 protein Tat potentiation of methamphetamine-induced decreases in evoked overflow of dopamine in the striatum of the rat. Brain Res. 984: 133– 142.

28. Chandler, L.,, H. Newsom,, C. Sumners, and, F. Crews. 1993. Chronic ethanol exposure potentiates NMDA excitotoxicity in cerebral cortical neurons. J. Neurochem. 60: 1578– 1581.

29. Chang, L.,, T. Ernst,, O. Speck, and, C. Grob. 2005. Additive effects of HIV and chronic methamphetamine use on brain metabolite abnormalities. Am. J. Psychiatry 162: 361– 369.

30. Chang, S.,, G. Wu,, N. Patel,, E. Vidal, and, M. Fiala. 1998. The effects of interaction between morphine and interleukin-1 on the immune response. Adv. Exp. Med. Biol. 437: 67– 72.

31. Chao, C.,, G. Gekker,, S. Hu,, W. Sheng,, K. Shark,, D. Bu,, S. Archer,, J. Bidlack, and, P. Peterson. 1996. Kappa opioid receptors in human microglia downregulate human immunodeficiency virus 1 expression. Proc. Natl. Acad. Sci. USA 93: 8051– 8056.

32. Chao, C.,, G. Gekker,, W. Sheng,, S. Hu, and, P. Peterson. 2001. U50488 inhibits HIV-1 expression in acutely infected monocyte-derived macrophages. Drug Alcohol Depend. 62: 149– 154.

33. Chauhan, A.,, J. Turchan,, C. Pocernich,, A. Bruce-Keller,, S. Roth,, D. Butterfield,, E. Major, and, A. Nath. 2003. Intracellular human immunodeficiency virus tat expression in astrocytes promotes astrocyte survival but induces potent neurotoxicity at distant sites via axonal transport. J. Biol. Chem. 278: 13512– 13519.

34. Chen, W.,, Z. Tang,, P. Fortina,, P. Patel,, S. Addya,, S. Surrey,, E. Acheampong,, M. Mukhtar, and, R. Pomerantz. 2005. Ethanol potentiates HIV-1 gp120-induced apoptosis in human neurons via both the death receptor and NMDA receptor pathways. Virology 334: 59– 73.

35. Chuang, Y.,, S. Suzuki,, T. Chuang,, T. Miyagi,, L. Chuang, and, R. Doi. 2005. Opioids and the progression of simian AIDS. Front. Biosci. 10: 1666– 1677.

36. Concha, M.,, O. Selnes,, D. Vlahov,, T. Nance-Sproson,, M. Updike,, W. Royal,, J. Palenicek, and, J. McArthur. 1997. Comparison of neuropsychological performance between AIDS-free injecting drug users and homosexual men. Neuroepidemiology 16: 78– 85.

37. Corasaniti, M.,, D. Amantea,, R. Russo,, S. Piccirilli,, A. Leta,, M. Corazzari,, G. Nappi, and, G. Bagetta. 2005. 17beta-Estradiol reduces neuronal apoptosis induced by HIV-1 gp120 in the neocortex of rat. Neurotoxicology 26: 893– 903.

38. Craig, J.,, and W. Mosier. 1978. Clinical and laboratory findings on admission to an alcohol detoxification service. Int. J. Addict. 13: 1207– 1215.

39. Croxford, J. 2003. Therapeutic potential of cannabinoids in CNS disease. CNS Drugs 17: 179– 202.

40. Cysique, L.,, P. Maruff, and, B. Brew. 2004. Antiretroviral therapy in HIV infection: are neurologically active drugs important? Arch. Neurol. 61: 1699– 1704.

41. Devaud, L.,, and A. Morrow. 1999. Gender-selective effects of ethanol dependence on NMDA receptor subunit expression in cerebral cortex, hippocampus and hypothalamus. Eur. J. Pharmacol. 369: 331– 334.

42. De Vries, T.,, A. Schoffelmeer,, R. Binnekade, and, L. Vanderschuren. 1999. Dopaminergic mechanisms mediating the incentive to seek cocaine and heroin following long-term withdrawal of IV drug self-administration. Psychopharmacology (Berlin) 143: 254– 260.

43. Diamond, I.,, and R. Messing. 1994. Neurologic effects of alcoholism. West. J. Med. 161: 279– 287.

44. Dingle, G.,, and T. Oei. 1997. Is alcohol a cofactor of HIV and AIDS? Evidence from immunological and behavioral studies. Psychol. Bull. 122: 56– 71.

45. Donahoe, R. 2004. Multiple ways that drug abuse might influence AIDS progression: clues from a monkey model. J. Neuroimmunol. 147: 28– 32.

46. Donahoe, R.,, and D. Vlahov. 1998. Opiates as potential cofactors in progression of HIV-1 infections to AIDS. J. Neuroimmunol. 83: 77– 87.

47. Dore, G.,, A. McDonald,, Y. Li,, J. Kaldor, and, B. Brew. 2003. Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 17: 1539– 1545.

48. Dronda, F.,, J. Zamora,, S. Moreno,, A. Moreno,, J. Casado,, A. Muriel,, M. Perez-Elias,, A. Antela,, L. Moreno, and, C. Quereda. 2004. CD4 cell recovery during successful antiretroviral therapy in naive HIV-infected patients: the role of intravenous drug use. AIDS 18: 2210– 2212.

49. Edelstein, H.,, and R. Knight. 1987. Severe parkinsonism in two AIDS patients taking prochlorperazine. Lancet ii: 341– 342. (Letter.)

50. El-Hage, N.,, J. Gurwell,, I. Singh,, P. Knapp,, A. Nath, and, K. Hauser. 2005. Synergistic increases in intracellular Ca2+, and the release of MCP-1, RANTES, and IL-6 by astrocytes treated with opiates and HIV-1 Tat. Glia 50: 91– 106.

51. Epstein, L.,, and H. Gelbard. 1999. HIV-1-induced neuronal injury in the developing brain. J. Leukoc. Biol. 65: 453– 457.

52. Ernst, T.,, L. Chang,, M. Leonido-Yee, and, O. Speck. 2000. Evidence for long-term neurotoxicity associated with methamphetamine abuse: A 1H MRS study. Neurology 54: 1344– 1349.

53. Fabris, P.,, G. Tositti,, V. Manfrin,, M. Giordani,, A. Vaglia,, A. Cattelan, and, A. Carlotto. 2000. Does alcohol intake affect highly active antiretroviral therapy (HAART) response in HIV-positive patients? J. Acquir. Immune Defic. Syndr. 25: 92– 93.

54. Fiala, M.,, A. Eshleman,, J. Cashman,, A. Lin,, J. Lossinsky,, V. Suarez,, W. Yang,, J. Zhang,, W. Popik,, E. Singer,, F. Chiappelli,, E. Carro,, M. Weinand,, M. Witte, and, J. Arthos. 2005. Cocaine increases human immunodeficiency virus type 1 neuroinvasion through remodeling brain microvascular endothelial cells. J. Neurovirol. 11: 281– 291.

55. Fiala, M.,, X. Gan,, L. Zhang,, S. House,, T. Newton,, M. Graves,, P. Shapshak,, M. Stins,, K. Kim,, M. Witte, and, S. Chang. 1998. Cocaine enhances monocyte migration across the blood-brain barrier. Cocaine’s connection to AIDS dementia and vasculitis? Adv. Exp. Med. Biol. 437: 199– 205.

56. Flexner, C.,, V. Cargill,, J. Sinclair,, T. Kresina, and, L. Cheever. 2001. Alcohol use can result in enhanced drug metabolism in HIV pharmacotherapy. AIDS Patient Care STDs 15: 57– 58.

57. Flora, G.,, Y. Lee,, A. Nath,, B. Hennig,, W. Maragos, and, M. Toborek. 2003. Methamphetamine potentiates HIV-1 Tat protein-mediated activation of redox-sensitive pathways in discrete regions of the brain. Exp. Neurol. 179: 60– 70.

58. Flora, G.,, H. Pu,, Y. Lee,, R. Ravikumar,, A. Nath,, B. Hennig, and, M. Toborek. 2005. Proinflammatory synergism of ethanol and HIV-1 Tat protein in brain tissue. Exp. Neurol. 191: 2– 12.

59. Foga, I.,, A. Nath,, B. Hasinoff, and, J. Geiger. 1997. Antioxidants and dipyridamole inhibit HIV-1 gp120-induced free radical-based oxidative damage to human monocytoid cells. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 16: 223– 229.

60. Garcia-Ratés, S.,, J. Camarasa,, E. Escubedo, and, D. Pubill. 2007. Methamphetamine and 3,4-methylenedioxymethamphetamine interact with central nicotinic receptors and induce their up-regulation. Toxicol. Appl. Pharmacol. 223: 195– 205.

61. Gelbard, H. 1999. Neuroprotective strategies for HIV-1-associated neurologic disease. Ann. N. Y. Acad. Sci. 890: 312– 313.

62. Goswami, R.,, S. Dawson, and, G. Dawson. 1998. Cyclic AMP protects against staurosporine and wortmannin-induced apoptosis and opioid-enhanced apoptosis in both embryonic and immortalized (F-11kappa7) neurons. J. Neurochem. 70: 1376– 1382.

63. Green, J.,, R. Saveanu, and, R. Bornstein. 2004. The effect of previous alcohol abuse on cognitive function in HIV infection. Am. J. Psychiatry 161: 249– 254.

64. Gundlah, C.,, S. Kohama,, S. Mirkes,, V. Garyfallou,, H. Urbanski, and, C. Bethea. 2000. Distribution of estrogen receptor beta (ERbeta) mRNA in hypothalamus, midbrain and temporal lobe of spayed macaque: continued expression with hormone replacement. Brain Res. Mol. Brain Res. 76: 191– 204.

65. Gurwell, J.,, A. Nath,, Q. Sun,, J. Zhang,, K. Martin,, Y. Chen, and, K. Hauser. 2001. Synergistic neurotoxicity of opioids and human immunodeficiency virus-1 Tat protein in striatal neurons in vitro. Neuroscience 102: 555– 563.

66. Hales, G.,, N. Roth, and, D. Smith. 2000. Possible fatal interaction between protease inhibitors and methamphetamine. Antivir. Ther. 5: 19. (Letter.)

67. Harrington, R.,, J. Woodward,, T. Hooton, and, J. Horn. 1999. Life-threatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and gamma-hydroxybutyrate. Arch. Intern. Med. 159: 2221– 2224.

68. Hauser, K.,, J. Foldes, and, C. Turbek. 1999. Dynorphin A (1-13) neurotoxicity in vitro: opioid and non-opioid mechanisms in mouse spinal cord neurons. Exp. Neurol. 160: 361– 375.

69. Hauser, K.,, J. Gurwell, and, C. Turbek. 1994. Morphine inhibits Purkinje cell survival and dendritic differentiation in organotypic cultures of the mouse cerebellum. Exp. Neurol. 130: 95– 105.

70. Hauser, K.,, M. Harris-White,, J. Jackson,, L. Opanashuk, and, J. Carney. 1998. Opioids disrupt Ca2+ homeostasis and induce carbonyl oxyradical production in mouse astrocytes in vitro: transient increases and adaptation to sustained exposure. Exp. Neurol. 151: 70– 76.

71. Hauser, K.,, A. Houdi,, C. Turbek,, R. Elde, and, W. Maxson. 2000. Opioids intrinsically inhibit the genesis of mouse cerebellar granule neuron precursors in vitro: differential impact of mu and delta receptor activation on proliferation and neurite elongation. Eur. J. Neurosci. 12: 1281– 1293.

72. Heaton, R.,, I. Grant,, N. Butters,, D. White,, D. Kirson,, J. Atkinson,, J. McCutchan,, M. Taylor,, M. Kelly,, R. J. Ellis, et al. 1995. The HNRC 500 — neuropsychology of HIV infection at different disease stages. J. Int. Neuropsychol. Soc. 1: 231– 251.

73. Henry, J.,, and I. Hill. 1998. Fatal interaction between ritonavir and MDMA. Lancet 352: 1751– 1752.

74. Hollander, H.,, J. Golden,, T. Mendelson, and, D. Cortland. 1985. Extrapyramidal symptoms in AIDS patients given low-dose metoclopramide or chlorpromazine. Lancet ii: 1186. (Letter.)

75. Hornykiewicz, O. 1998. Biochemical aspects of Parkinson’s disease. Neurology 51: S2– S9.

76. Hriso, E.,, T. Kuhn,, J. Masdeu, and, M. Grundman. 1991. Extrapyramidal symptoms due to dopamine-blocking agents in patients with AIDS encephalopathy. Am. J. Psychiatry 148: 1558– 1561.

77. Hu, S.,, W. Sheng,, J. Lokensgard, and, P. Peterson. 2002. Morphine induces apoptosis of human microglia and neurons. Neuropharmacology 42: 829– 836.

78. Hu, S.,, W. Sheng,, J. Lokensgard, and, P. Peterson. 2005. Morphine potentiates HIV-1 gp120-induced neuronal apoptosis. J. Infect. Dis. 191: 886– 889.

79. Hu, X.,, and M. Ticku. 1995. Chronic ethanol treatment upregulates the NMDA receptor function and binding in mammalian cortical neurons. Brain Res. Mol. Brain Res. 30: 347– 356.

80. Jenuwein, M.,, C. Scheller,, E. Neuen-Jacob,, S. Sopper,, T. Tatschner,, V. ter Meulen,, P. Riederer, and, E. Koutsilieri. 2004. Dopamine deficits and regulation of the cAMP second messenger system in brains of simian immunodeficiency virus-infected rhesus monkeys. J. Neurovirol. 10: 163– 170.

81. Jernigan, T.,, A. Gamst,, S. Archibald,, C. Fennema-Notestine,, M. Mindt,, T. Marcotte,, R. Heaton,, R. Ellis, and, I. Grant. 2005. Effects of methamphetamine dependence and HIV infection on cerebral morphology. Am. J. Psychiatry 162: 1461– 1472.

82. Johnson-Greene, D.,, K. Adams,, S. Gilman,, R. Koeppe,, L. Junck,, K. Kluin,, S. Martorello, and, M. Heumann. 1997. Effects of abstinence and relapse upon neuropsychological function and cerebral glucose metabolism in severe chronic alcoholism. J. Clin. Exp. Neuropsychol. 19: 378– 385.

83. Kapadia, F.,, J. Cook,, M. Cohen,, N. Sohler,, A. Kovacs,, R. Greenblatt,, I. Choudhary, and, D. Vlahov. 2005. The relationship between non-injection drug use behaviors on progression to AIDS and death in a cohort of HIV seropositive women in the era of highly active antiretroviral therapy use. Addiction 100: 990– 1002.

84. Kendall, S.,, C. Anderson,, A. Nath,, J. Turchan-Cholewo,, C. Land,, C. Mactutus, and, R. Booze. 2005. Gonadal steroids differentially modulate neurotoxicity of HIV and cocaine: testosterone and ICI 182,780 sensitive mechanism. BMC Neurosci. 6: 40– 52.

85. Khurdayan, V.,, S. Buch,, N. El-Hage,, S. Lutz,, S. Goebel,, I. Singh,, P. Knapp,, J. Turchan-Cholewo,, A. Nath, and, K. Hauser. 2004. Preferential vulnerability of astroglia and glial precursors to combined opioid and HIV-1 Tat exposure in vitro. Eur. J. Neurosci. 19: 3171– 3182.

86. Kieburtz, K.,, L. Epstein,, H. Gelbard, and, J. Greenamyre. 1991. Excitotoxicity and dopaminergic dysfunction in the acquired immunodeficiency syndrome dementia complex. Therapeutic implications. Arch. Neurol. 48: 1281– 1284.

87. Kindlundh-Högberg, A.,, H. Schiöth, and, P. Svenningsson. 2007. Repeated intermittent MDMA binges reduce DAT density in mice and SERT density in rats in reward regions of the adolescent brain. Neurotoxicology 28: 1158– 1169.

88. Kofke, W.,, R. Garman,, R. Garman, and, M. Rose. 1999. Opioid neurotoxicity: fentanyl-induced exacerbation of cerebral ischemia in rats. Brain Res. 818: 326– 334.

89. Kofke, W.,, R. Garman,, R. Stiller,, M. Rose, and, R. Garman. 1996. Opioid neurotoxicity: fentanyl dose-response effects in rats. Anesth. Analg. 83: 1298– 1306.

90. Koob, G. 2000. Neurobiology of addiction. Toward the development of new therapies. Ann. N. Y. Acad. Sci. 909: 170– 185.

91. Kosel, B.,, F. Aweeka,, N. Benowitz,, S. Shade,, J. Hilton,, P. Lizak, and, D. Abrams. 2002. The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir. AIDS 16: 543– 550.

92. Koutsilieri, E.,, M. Gotz,, S. Sopper,, U. Sauer,, M. Demuth,, V. ter Meulen, and, P. Riederer. 1997a. Regulation of glutathione and cell toxicity following exposure to neurotropic substances and human immunodeficiency virus-1 in vitro. J. Neurovirol. 3: 342– 349.

93. Koutsilieri, E.,, M. Gotz,, S. Sopper,, C. Stahl-Hennig,, M. Czub,, V. ter Meulen, and, P. Riederer. 1997b. Monoamine metabolite levels in CSF of SIV-infected rhesus monkeys ( Macaca mulatta). Neuroreport 8: 3833– 3836.

94. Kreek, M. 2001. Drug addictions. Molecular and cellular endpoints. Ann. N. Y. Acad. Sci. 937: 27– 49.

95. Kreek, M.,, and G. Koob. 1998. Drug dependence: stress and dysregulation of brain reward pathways. Drug Alcohol Depend. 51: 23– 47.

96. Kumar, R.,, A. Perez-Casanova,, G. Tirado,, R. Noel,, C. Torres,, I. Rodriguez,, M. Martinez,, S. Staprans,, E. Kraiselburd,, Y. Yamamura,, J. Higley, and, A. Kumar. 2005. Increased viral replication in simian immunodeficiency virus/simian-HIV-infected macaques with self-administering model of chronic alcohol consumption. J. Acquir. Immune Defic. Syndr. 39: 386– 390.

97. Kumar, R.,, C. Torres,, Y. Yamamura,, I. Rodriguez,, M. Martinez,, S. Staprans,, R. Donahoe,, E. Kraiselburd,, E. Stephens, and, A. Kumar. 2004. Modulation by morphine of viral set point in rhesus macaques infected with simian immunodeficiency virus and simian-human immunodeficiency virus. J. Virol. 78: 11425– 11428.

98. Kurling, S.,, A. Kankaanpaa,, S. Ellermaa,, T. Karila, and, T. Seppala. 2005. The effect of sub-chronic nandrolone decanoate treatment on dopaminergic and serotonergic neuronal systems in the brains of rats. Brain Res. 1044: 67– 75.

99. Langford, D.,, A. Adame,, A. Grigorian,, I. Grant,, J. McCutchan,, R. Ellis,, T. Marcotte, and, E. Masliah. 2003. Patterns of selective neuronal damage in methamphetamine-user AIDS patients. J. Acquir. Immune Defic. Syndr. 34: 467– 474.

100. Langford, D.,, A. Grigorian,, R. Hurford,, A. Adame,, L. Crews, and, E. Masliah. 2004. The role of mitochondrial alterations in the combined toxic effects of human immunodeficiency virus Tat protein and methamphetamine on calbindin positive-neurons. J. Neurovirol. 10: 327– 337.

101. Larsson, M.,, L. Hagberg,, A. Forsman, and, G. Norkrans. 1991. Cerebrospinal fluid catecholamine metabolites in HIV-infected patients. J. Neurosci. Res. 28: 406– 409.

102. Lipton, S. 1998. Neuronal injury associated with HIV-1: approaches to treatment. Annu. Rev. Pharmacol. Toxicol. 38: 159– 177.

103. Littleton, J.,, and H. Little. 1994. Current concepts of ethanol dependence. Addiction 89: 1397– 1412.

104. Lopez, O.,, J. Becker,, M. Dew, and, R. Caldararo. 2004. Risk modifiers for peripheral sensory neuropathy in HIV infection/AIDS. Eur. J. Neurol. 11: 97– 102.

105. Mahajan, S.,, R. Aalinkeel,, J. Reynolds,, B. Nair,, S. Fernandez,, S. Schwartz, and, M. Nair. 2005a. Morphine exacerbates HIV-1 viral protein gp120 induced modulation of chemokine gene expression in U373 astrocytoma cells. Curr. HIV Res. 3: 277– 288.

106. Mahajan, S.,, S. Schwartz,, R. Aalinkeel,, R. Chawda,, D. Sykes, and, M. Nair. 2005b. Morphine modulates chemokine gene regulation in normal human astrocytes. Clin. Immunol. 115: 323– 332.

107. Manly, J.,, C. Merchant,, D. Jacobs,, S. Small,, K. Bell,, M. Ferin, and, R. Mayeux. 2000. Endogenous estrogen levels and Alzheimer’s disease among postmenopausal women. Neurology 54: 833– 837.

108. Maragos, W.,, K. Young,, J. Turchan,, M. Guseva,, J. Pauly,, A. Nath, and, W. Cass. 2002. Human immunodeficiency virus-1 Tat protein and methamphetamine interact synergistically to impair striatal dopaminergic function. J. Neurochem. 83: 955– 963.

109. Marcario, J.,, K. Manaye,, K. SantaCruz,, P. Mouton,, N. Berman, and, P. Cheney. 2004. Severe subcortical degeneration in macaques infected with neurovirulent simian immunodeficiency virus. J. Neurovirol. 10: 387– 399.

110. McArthur, J.,, N. Haughey,, S. Gartner,, K. Conant,, C. Pardo,, A. Nath, and, N. Sacktor. 2003. Human immunodeficiency virus-associated dementia: an evolving disease. J. Neurovirol. 9: 205– 221.

111. McCarthy, L.,, M. Wetzel,, J. Sliker,, T. Eisenstein, and, T. Rogers. 2001. Opioids, opioid receptors, and the immune response. Drug Alcohol Depend. 62: 111– 123.

112. Mellon, R.,, and B. Bayer. 1998. Evidence for central opioid receptors in the immunomodulatory effects of morphine: review of potential mechanism(s) of action. J. Neuroimmunol. 83: 19– 28.

113. Meriney, S.,, M. Ford,, D. Oliva, and, G. Pilar. 1991. Endogenous opioids modulate neuronal survival in the developing avian ciliary ganglion. J. Neurosci. 11: 3705– 3717.

114. Meyerhoff, D.,, S. MacKay,, D. Sappey-Marinier,, R. Deicken,, G. Calabrese,, W. P. Dillon,, M. W. Weiner, and, G. Fein. 1995. Effects of chronic alcohol abuse and HIV infection on brain phosphorus metabolites. Alcohol Clin. Exp. Res. 19: 685– 692.

115. Mirsattari, S.,, M. Berry,, J. Holden,, W. Ni,, A. Nath, and, C. Power. 1999. Paroxysmal dyskinesias in patients with HIV infection. Neurology 52: 109– 114.

116. Mirsattari, S.,, C. Power, and, A. Nath. 1998. Parkinsonism with HIV infection. Mov. Disord. 13: 684– 689.

117. Morgello, S.,, L. Estanislao,, D. Simpson,, A. Geraci,, A. DiRocco,, P. Gerits,, E. Ryan,, T. Yakoushina,, S. Khan,, R. Mahboob,, M. Naseer,, D. Dorfman, and, V. Sharp. 2004. HIV-associated distal sensory polyneuropathy in the era of highly active antiretroviral therapy: the Manhattan HIV Brain Bank. Arch. Neurol. 61: 546– 551.

118. Murrill, C.,, H. Weeks,, B. Castrucci,, H. Weinstock,, B. Bell,, C. Spruill, and, M. Gwinn. 2002. Age-specific seroprevalence of HIV, hepatitis B virus, and hepatitis C virus infection among injection drug users admitted to drug treatment in 6 US cities. Am. J. Public Health 92: 385– 387.

119. Nair, M.,, S. Mahajan,, S. Schwartz,, J. Reynolds,, R. Whitney,, Z. Bernstein,, R. Chawda,, D. Sykes,, R. Hewitt, and, C. Hsiao. 2005. Cocaine modulates dendritic cell-specific C type intercellular adhesion molecule-3-grabbing nonintegrin expression by dendritic cells in HIV-1 patients. J. Immunol. 174: 6617– 6626.

120. Nair, M.,, S. Schwartz,, S. Mahajan,, C. Tsiao,, R. Chawda,, R. Whitney,, B. Don Sykes, and, R. Hewitt. 2004. Drug abuse and neuropathogenesis of HIV infection: role of DC-SIGN and IDO. J. Neuroimmunol. 157: 56– 60.

121. Nair, M.,, S. Schwartz,, R. Polasani,, J. Hou,, A. Sweet, and, K. Chadha. 1997. Immunoregulatory effects of morphine on human lymphocytes. Clin. Diagn. Lab. Immunol. 4: 127– 132.

122. Nath, A.,, and J. Geiger. 1998. Neurobiological aspects of HIV infections: neurotoxic mechanisms. Prog. Neurobiol. 54: 19– 33.

123. Nath, A.,, W. Maragos,, M. Avison,, F. Schmitt, and, J. Berger. 2001. Accelerated HIV dementia with methamphetamine and cocaine use. J. Neurovirol. 7: 66– 71.

124. Nestler, E.,, and G. Aghajanian. 1997. Molecular and cellular basis of addiction. Science 278: 58– 63.

125. Neuenburg, J.,, H. Brodt,, B. Herndier,, M. Bickel,, P. Bacchetti,, R. Price,, R. Grant, and, W. Schlote. 2002. HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 31: 171– 177.

126. Parsons, J.,, E. Rosof,, J. Punzalan, and, L. Di Maria. 2005. Integration of motivational interviewing and cognitive behavioral therapy to improve HIV medication adherence and reduce substance use among HIV-positive men and women: results of a pilot project. AIDS Patient Care STDs 19: 31– 39.

127. Pascual-Leone, A.,, and A. Dhuna. 1990. Cocaine-associated multifocal tics. Neurology 40: 999– 1000.

128. Pascual-Leone, A.,, A. Dhuna,, I. Altafullah, and, D. Anderson. 1990. Cocaine-induced seizures. Neurology 40: 404– 407.

129. Peterson, P.,, G. Gekker,, S. Hu,, J. Lokensgard,, P. Portoghese, and, C. Chao. 1999. Endomorphin-1 potentiates HIV-1 expression in human brain cell cultures: implication of an atypical mu-opioid receptor. Neuropharmacology 38: 273– 278.

130. Peterson, P.,, G. Gekker,, J. Lokensgard,, J. Bidlack,, A. Chang,, X. Fang, and, P. Portoghese. 2001. kappa-Opioid receptor agonist suppression of HIV-1 expression in CD4(+) lymphocytes. Biochem. Pharmacol. 61: 1145– 1151.

131. Peterson, P.,, G. Gekker,, R. Schut,, S. Hu,, H. Balfour, and, C. Chao. 1993. Enhancement of HIV-1 replication by opiates and cocaine: the cytokine connection. Adv. Exp. Med. Biol. 335: 181– 188.

132. Pillai, R.,, B. S. Nair, and, R. R. Watson. 1991. AIDS, drugs of abuse and the immune system: a complex immunotoxicological network. Arch. Toxicol. 65: 609– 617.

133. Polakiewicz, R.,, M. Schieferl,, A. Gingras,, N. Sonenberg, and, M. Comb. 1998. mu-Opioid receptor activates signaling pathways implicated in cell survival and translational control. J. Biol. Chem. 273: 23534– 23541.

134. Prendergast, M.,, B. Harris,, J. Blanchard,, S. Mayer,, D. Gibson, and, J. Littleton. 2000. In vitro effects of ethanol withdrawal and spermidine on viability of hippocampus from male and female rat. Alcohol Clin. Exp. Res. 24: 1855– 1861.

135. Prendergast, M.,, B. Harris,, P. Mullholland,, J. Blanchard,, D. Gibson,, R. Holley, and, J. Littleton. 2004. Hippocampal CA1 region neurodegeneration produced by ethanol withdrawal requires activation of intrinsic polysynaptic hippocampal pathways and function of N-methyl-D-aspartate receptors. Neuroscience 124: 869– 877.

136. Prentiss, D.,, R. Power,, G. Balmas,, G. Tzuang, and, D. Israelski. 2004. Patterns of marijuana use among patients with HIV/AIDS followed in a public health care setting. J. Acquir. Immune Defic. Syndr. 35: 38– 45.

137. Pu, H.,, J. Tian,, G. Flora,, Y. Lee,, A. Nath,, B. Hennig, and, M. Toborek. 2003. HIV-1 Tat protein upregulates inflammatory mediators and induces monocyte invasion into the brain. Mol. Cell. Neurosci. 24: 224– 237.

138. Rabkin, J.,, M. McElhiney, and, S. Ferrando. 2004. Mood and substance use disorders in older adults with HIV/AIDS: methodological issues and preliminary evidence. AIDS 181: S43– S48.

139. Reiter, G. 1996. The HIV wasting syndrome. AIDS Clin. Care 8: 89– 91, 93, 96.

140. Reyes, M.,, F. Faraldi,, C. Senseng,, C. Flowers, and, R. Fariello. 1991. Nigral degeneration in acquired immune deficiency syndrome (AIDS). Acta Neuropathol. 82: 39– 44.

141. Robinson, T. E.,, and K. C. Berridge. 2000. The psychology and neurobiology of addiction: an incentive-sensitization view. Addiction 95 (Suppl. 2): S91– S117.

142. Rogers, T.,, and P. Peterson. 2003. Opioid G protein-coupled receptors: signals at the crossroads of inflammation. Trends Immunol. 24: 116– 121.

143. Rooney, K.,, R. Armstrong, and, R. Sewell. 1991. Increased dopamine receptor sensitivity in the rat following acute administration of sufentanil, U50,488H and D-Ala2-D-Leu5-enkephalin. Naunyn Schmiedebergs Arch. Pharmacol. 343: 458– 462.

144. Rudolph, J.,, J. Lemasters, and, F. Crews. 1998. Effects of chronic ethanol exposure on oxidation and NMDA-stimulated neuronal death in primary cortical neuronal cultures. Alcohol Clin. Exp. Res. 22: 2080– 2085.

145. Russo, R.,, M. Navarra,, J. Maiuolo,, D. Rotiroti,, G. Bagetta, and, M. Corasaniti. 2005. 17beta-Estradiol protects SH-SY5Y cells against HIV-1 gp120-induced cell death: evidence for a role of estrogen receptors. Neurotoxicology 26: 905– 913.

146. Sacktor, N. 2002. The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. J. Neurovirol. 8 (Suppl. 2): 115– 121.

147. Sacktor, N.,, M. McDermott,, K. Marder,, G. Schifitto,, O. Selnes,, J. McArthur,, Y. Stern,, S. Albert,, D. Palumbo,, K. Kieburtz,, J. De Marcaida,, B. Cohen, and, L. Epstein. 2002. HIV-associated cognitive impairment before and after the advent of combination therapy. J. Neurovirol. 8: 136– 142.

148. Saunders-Pullman, R.,, J. Gordon-Elliott,, M. Parides,, S. Fahn,, H. Saunders, and, S. Bressman. 1999. The effect of estrogen replacement on early Parkinson’s disease. Neurology 52: 1417– 1421.

149. Schoffelmeer, A.,, F. Hogenboom, and, A. Mulder. 1997. Kappa1- and kappa2-opioid receptors mediating presynaptic inhibition of dopamine and acetylcholine release in rat neostriatum. Br. J. Pharmacol. 122: 520– 524.

150. Self, R.,, P. Mulholland,, B. Harris,, A. Nath, and, M. Prendergast. 2004. Cytotoxic effects of exposure to the human immunodeficiency virus type 1 protein Tat in the hippocampus are enhanced by prior ethanol treatment. Alcohol Clin. Exp. Res. 28: 1916– 1924.

151. Singhal, P.,, A. Kapasi,, K. Reddy,, N. Franki,, N. Gibbons, and, G. Ding. 1999. Morphine promotes apoptosis in Jurkat cells. J. Leukoc. Biol. 66: 650– 658.

152. Singhal, P.,, K. Reddy,, N. Franki,, V. Sanwal, and, N. Gibbons. 1997. Morphine induces splenocyte apoptosis and enhanced mRNA expression of cathepsin-B. Inflammation 21: 609– 617.

153. Singhal, P.,, P. Sharma,, A. Kapasi,, K. Reddy,, N. Franki, and, N. Gibbons. 1998. Morphine enhances macrophage apoptosis. J. Immunol. 160: 1886– 1893.

154. Slooter, A.,, J. Bronzova,, J. Witteman,, C. Van Broeckhoven,, A. Hofman, and, C. van Duijn. 1999. Estrogen use and early onset Alzheimer’s disease: a population-based study. J. Neurol. Neurosurg. Psychiatry 67: 779– 781.

155. Stefano, G. 1999. Substance abuse and HIV-gp120: are opiates protective? Arch. Immunol. Ther. Exp. 47: 99– 106.

156. Stein, M.,, D. Herman,, E. Trisvan,, P. Pirraglia,, P. Engler, and, B. Anderson. 2005. Alcohol use and sexual risk behavior among human immunodeficiency virus-positive persons. Alcohol Clin. Exp. Res. 29: 837– 843.

157. Stiene-Martin, A.,, R. Zhou, and, K. Hauser. 1998. Regional, developmental, and cell cycle-dependent differences in mu, delta, and kappa-opioid receptor expression among cultured mouse astrocytes. Glia 22: 249– 259.

158. Stocker, H.,, G. Kruse,, P. Kreckel,, C. Herzmann,, K. Arasteh,, J. Claus,, H. Jessen,, C. Cordes,, B. Hintsche,, F. Schlote,, L. Schneider, and, M. Kurowski. 2004. Nevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 48: 4148– 4153.

159. Tabakoff, B. 1994. Alcohol and AIDS—is the relationship all in our heads? Alcohol Clin. Exp. Res. 18: 415– 416.

160. Thomas, D.,, and D. Kuhn. 2005. MK-801 and dextromethorphan block microglial activation and protect against methamphetamine-induced neurotoxicity. Brain Res. 1050: 190– 198.

161. Toborek, M.,, Y. Lee,, H. Pu,, A. Malecki,, G. Flora,, R. Garrido,, B. Hennig,, H. Bauer, and, A. Nath. 2003. HIV-Tat protein induces oxidative and inflammatory pathways in brain endothelium. J. Neurochem. 84: 169– 179.

162. Tomlinson, G.,, P. Simmonds,, A. Busuttil,, A. Chiswick, and, J. Bell. 1999. Upregulation of microglia in drug users with and without pre-symptomatic HIV infection. Neuropathol. Appl. Neurobiol. 25: 369– 379.

163. Turchan, J.,, C. Anderson,, K. Hauser,, Q. Sun,, J. Zhang,, Y. Liu,, P. Wise,, I. Kruman,, W. Maragos,, M. Mattson,, R. Booze, and, A. Nath. 2001. Estrogen protects against the synergistic toxicity by HIV proteins, methamphetamine and cocaine. BMC Neurosci. 2: 3– 13.

164. Turchan, J.,, C. Pocernich,, C. Gairola,, A. Chauhan,, G. Schifitto,, D. Butterfield,, S. Buch,, O. Narayan,, A. Sinai,, J. Geiger,, J. Berger,, H. Elford, and, A. Nath. 2003. Oxidative stress in HIV demented patients and protection ex vivo with novel antioxidants. Neurology 60: 307– 314.

165. Tyor, W.,, and L. Middaugh. 1999. Do alcohol and cocaine abuse alter the course of HIV-associated dementia complex? J. Leukoc. Biol. 65: 475– 481.

166. Vanderschuren, L.,, G. Wardeh,, T. J. De Vries,, A. H. Mulder, and, A. Schoffelmeer. 1999. Opposing role of dopamine D1 and D2 receptors in modulation of rat nucleus accumbens noradrenaline release. J. Neurosci. 19: 4123– 4131.

167. Vlahov, D.,, N. Galai,, M. Safaeian,, S. Galea,, G. Kirk,, G. Lucas, and, T. Sterling. 2005. Effectiveness of highly active antiretroviral therapy among injection drug users with late-stage human immunodeficiency virus infection. Am. J. Epidemiol. 161: 999– 1012.

168. Walker, D.,, M. Heaton,, N. Lee,, M. King, and, B. Hunter. 1993. Effect of chronic ethanol on the septohippocampal system: a role for neurotrophic factors? Alcohol Clin. Exp. Res. 17: 12– 18.

169. Wang, G.,, L. Chang,, N. Volkow,, F. Telang,, J. Logan,, T. Ernst, and, J. Fowler. 2004. Decreased brain dopaminergic transporters in HIV-associated dementia patients. Brain 127: 2452– 2458.

170. Wang, X.,, N. Tan,, S. Douglas,, T. Zhang,, Y. Wang, and, W. Ho. 2005. Morphine inhibits CD8+ T cell-mediated, noncytolytic, anti-HIV activity in latently infected immune cells. J. Leukoc. Biol. 78: 772– 776.

171. Ware, N.,, M. Wyatt, and, T. Tugenberg. 2005. Adherence, stereotyping and unequal HIV treatment for active users of illegal drugs. Soc. Sci. Med. 61: 565– 576.

172. Watzl, B.,, and R. Watson. 1992. Role of alcohol abuse in nutritional immunosuppression. J. Nutr. 122: 733– 737.

173. Weiner, W.,, A. Rabinstein,, B. Levin,, C. Weiner, and, L. Shulman. 2001. Cocaine-induced persistent dyskinesias. Neurology 56: 964– 965.

174. Weinhardt, L.,, M. Carey,, K. Carey,, S. Maisto, and, C. Gordon. 2001. The relation of alcohol use to HIV-risk sexual behavior among adults with a severe and persistent mental illness. J. Consult. Clin. Psychol. 69: 77– 84.

175. Welch, K.,, and A. Morse. 2002. The clinical profile of end-stage AIDS in the era of highly active antiretroviral therapy. AIDS Patient Care STDs 16: 75– 81.

176. Wilson, J.,, K. Kalasinsky,, A. Levey,, C. Bergeron,, G. Reiber,, R. Anthony,, G. Schmunk,, K. Shannak,, J. Haycock, and, S. Kish. 1996a. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat. Med. 2: 699– 703.

177. Wilson, J.,, A. Levey,, C. Bergeron,, K. Kalasinsky,, L. Ang,, F. Peretti,, V. Adams,, J. Smialek,, W. Anderson,, K. Shannak,, J. Deck,, H. Niznik, and, S. Kish. 1996b. Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users. Ann. Neurol. 40: 428– 439.

178. Woolridge, E.,, S. Barton,, J. Samuel,, J. Osorio,, A. Dougherty, and, A. Holdcroft. 2005. Cannabis use in HIV for pain and other medical symptoms. J. Pain Symptom Manage. 29: 358– 367.

179. Wynn, G.,, K. Cozza,, M. Zapor,, G. Wortmann, and, S. Armstrong. 2005. Med-psych drug-drug interactions update. Antiretrovirals, part III: antiretrovirals and drugs of abuse. Psychosomatics 46: 79– 87.

180. Yin, D.,, R. Mufson,, R. Wang, and, Y. Shi. 1999. Fas-mediated cell death promoted by opioids. Nature 397: 218. (Letter.)

181. Yin, D.,, X. Ren,, Z. L. Zheng,, L. Pu,, L. Z. Jiang,, L. Ma, and, G. Pei. 1997. Etorphine inhibits cell growth and induces apoptosis in SK-N-SH cells: involvement of pertussis toxin-sensitive G proteins. Neurosci. Res. 29: 121– 127.